123 related articles for article (PubMed ID: 33548803)
41. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.
Chu ZL; Jones RM; He H; Carroll C; Gutierrez V; Lucman A; Moloney M; Gao H; Mondala H; Bagnol D; Unett D; Liang Y; Demarest K; Semple G; Behan DP; Leonard J
Endocrinology; 2007 Jun; 148(6):2601-9. PubMed ID: 17289847
[TBL] [Abstract][Full Text] [Related]
42. APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL/6 mice.
Bahirat UA; Shenoy RR; Goel RN; Nemmani KV
Eur J Pharmacol; 2017 Apr; 801():35-45. PubMed ID: 28274625
[TBL] [Abstract][Full Text] [Related]
43. Discovery of novel somatostatin receptor subtype 5 (SSTR5) antagonists: Pharmacological studies and design to improve pharmacokinetic profiles and human Ether-a-go-go-related gene (hERG) inhibition.
Yamasaki T; Hirose H; Yamashita T; Takakura N; Morimoto S; Nakahata T; Kina A; Nakano Y; Okano Tamura Y; Sugama J; Odani T; Shimizu Y; Iwasaki S; Watanabe M; Maekawa T; Kasai S
Bioorg Med Chem; 2017 Aug; 25(15):4153-4162. PubMed ID: 28622905
[TBL] [Abstract][Full Text] [Related]
44. 2,4-Diaminothienopyrimidines as orally active antimalarial agents.
González Cabrera D; Le Manach C; Douelle F; Younis Y; Feng TS; Paquet T; Nchinda AT; Street LJ; Taylor D; de Kock C; Wiesner L; Duffy S; White KL; Zabiulla KM; Sambandan Y; Bashyam S; Waterson D; Witty MJ; Charman SA; Avery VM; Wittlin S; Chibale K
J Med Chem; 2014 Feb; 57(3):1014-22. PubMed ID: 24446664
[TBL] [Abstract][Full Text] [Related]
45. Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ether-a-go-go-Related Gene (hERG) Liabilities.
Sakauchi N; Kohara Y; Sato A; Suzaki T; Imai Y; Okabe Y; Imai S; Saikawa R; Nagabukuro H; Kuno H; Fujita H; Kamo I; Yoshida M
J Med Chem; 2016 Apr; 59(7):2989-3002. PubMed ID: 26954848
[TBL] [Abstract][Full Text] [Related]
46. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
Wacker DA; Wang Y; Broekema M; Rossi K; O'Connor S; Hong Z; Wu G; Malmstrom SE; Hung CP; LaMarre L; Chimalakonda A; Zhang L; Xin L; Cai H; Chu C; Boehm S; Zalaznick J; Ponticiello R; Sereda L; Han SP; Zebo R; Zinker B; Luk CE; Wong R; Everlof G; Li YX; Wu CK; Lee M; Griffen S; Miller KJ; Krupinski J; Robl JA
J Med Chem; 2014 Sep; 57(18):7499-508. PubMed ID: 25208139
[TBL] [Abstract][Full Text] [Related]
47. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes.
Yoshida S; Tanaka H; Oshima H; Yamazaki T; Yonetoku Y; Ohishi T; Matsui T; Shibasaki M
Biochem Biophys Res Commun; 2010 Oct; 400(4):745-51. PubMed ID: 20816753
[TBL] [Abstract][Full Text] [Related]
48. Halide ion effects on human Ether-à-go-go related gene potassium channel properties.
Zeng H; Balasubramanian B; Penniman JR; Kinose F; Salata JJ; Lagrutta A
Assay Drug Dev Technol; 2013; 11(9-10):544-50. PubMed ID: 24147984
[TBL] [Abstract][Full Text] [Related]
49. Synthesis and SAR studies of bicyclic amine series GPR119 agonists.
Sakairi M; Kogami M; Torii M; Kataoka H; Fujieda H; Makino M; Kataoka D; Okamoto R; Miyazawa T; Okabe M; Inoue M; Takahashi N; Harada S; Watanabe N
Bioorg Med Chem Lett; 2012 Aug; 22(15):5123-8. PubMed ID: 22765901
[TBL] [Abstract][Full Text] [Related]
50. Synthesis and structure-activity relationship of 4-amino-2-phenylpyrimidine derivatives as a series of novel GPR119 agonists.
Negoro K; Yonetoku Y; Maruyama T; Yoshida S; Takeuchi M; Ohta M
Bioorg Med Chem; 2012 Apr; 20(7):2369-75. PubMed ID: 22365911
[TBL] [Abstract][Full Text] [Related]
51. Angelica dahurica Extracts Improve Glucose Tolerance through the Activation of GPR119.
Park EY; Kim EH; Kim CY; Kim MH; Choung JS; Oh YS; Moon HS; Jun HS
PLoS One; 2016; 11(7):e0158796. PubMed ID: 27391814
[TBL] [Abstract][Full Text] [Related]
52. Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.
Berglund S; Egner BJ; Gradén H; Gradén J; Morgan DG; Inghardt T; Giordanetto F
Bioorg Med Chem Lett; 2009 Aug; 19(15):4274-9. PubMed ID: 19500982
[TBL] [Abstract][Full Text] [Related]
53. [The role of pharmacology to produce firuglipel (DS-8500a), an orally available GPR119 agonist for type 2 diabetes mellitus].
Matsumoto K; Yoshitomi T; Shimada T
Nihon Yakurigaku Zasshi; 2018; 152(3):119-124. PubMed ID: 30185729
[TBL] [Abstract][Full Text] [Related]
54. Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes.
Mikami S; Kitamura S; Negoro N; Sasaki S; Suzuki M; Tsujihata Y; Miyazaki T; Ito R; Suzuki N; Miyazaki J; Santou T; Kanzaki N; Funami M; Tanaka T; Yasuma T; Momose Y
J Med Chem; 2012 Apr; 55(8):3756-76. PubMed ID: 22428944
[TBL] [Abstract][Full Text] [Related]
55. The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119.
Li G; Meng B; Yuan B; Huan Y; Zhou T; Jiang Q; Lei L; Sheng L; Wang W; Gong N; Lu Y; Ma C; Li Y; Shen Z; Huang H
Eur J Med Chem; 2020 Feb; 188():112017. PubMed ID: 31926470
[TBL] [Abstract][Full Text] [Related]
56. Oral 2-oleyl glyceryl ether improves glucose tolerance in mice through the GPR119 receptor.
Hassing HA; Engelstoft MS; Sichlau RM; Madsen AN; Rehfeld JF; Pedersen J; Jones RM; Holst JJ; Schwartz TW; Rosenkilde MM; Hansen HS
Biofactors; 2016 Nov; 42(6):665-673. PubMed ID: 27297962
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT₆ receptor antagonists.
Nirogi R; Shinde A; Daulatabad A; Kambhampati R; Gudla P; Shaik M; Gampa M; Balasubramaniam S; Gangadasari P; Reballi V; Badange R; Bojja K; Subramanian R; Bhyrapuneni G; Muddana N; Jayarajan P
J Med Chem; 2012 Nov; 55(21):9255-69. PubMed ID: 23006002
[TBL] [Abstract][Full Text] [Related]
58. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.
Bridgland-Taylor MH; Hargreaves AC; Easter A; Orme A; Henthorn DC; Ding M; Davis AM; Small BG; Heapy CG; Abi-Gerges N; Persson F; Jacobson I; Sullivan M; Albertson N; Hammond TG; Sullivan E; Valentin JP; Pollard CE
J Pharmacol Toxicol Methods; 2006; 54(2):189-99. PubMed ID: 16563806
[TBL] [Abstract][Full Text] [Related]
59. Novel 5-nitropyrimidine derivatives bearing endo-azabicyclic alcohols/amines as potent GPR119 agonists.
Fang Y; Yang Z; Gundeti S; Lee J; Park H
Bioorg Med Chem; 2017 Jan; 25(1):254-260. PubMed ID: 27825553
[TBL] [Abstract][Full Text] [Related]
60. Optimisation of novel 4, 8-disubstituted dihydropyrimido[5,4-
Fang Y; Zhang S; Li M; Xiong L; Tu L; Xie S; Jin Y; Liu Y; Yang Z; Liu R
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):50-58. PubMed ID: 31656107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
